# Inhibitory Effects of Far-Infrared Ray-Emitting Belts on Primary Dysmenorrhea

Authors: Ben-Yi Liau; Ting-Kai Leung; Ming-Chiu Ou; Cheng-Kun Ho; Aiga Yang; Yung-Sheng Lin
Journal: International Journal of Photoenergy
 (2012)

---

## Abstract

This study investigated the therapeutic effect of the far-infrared ray-emitting belt (FIRB) in the management of primary dysmenorrhea in female patients. Forty adolescent females with primary dysmenorrhea were enrolled in the study. Quantitative measurements were taken during the menstruation. Several parameters were measured and compared, including temperature, abdominal blood flow, heart rate variability, and pain assessment. Statistical analysis shows that treatment with FIRB had significant efficiency in increasing regional surface temperature and abdominal blood flow, widening standard deviation of normal-to-normal RR intervals, and reducing VRS and NRS pain scores. The application of an FIRB appears to alleviate dysmenorrhea.


---

## Body

## 1. Introduction

Dysmenorrhea is one of the gynecological symptoms pertaining obviously to women. Ninety percent of women experienced menstrual pain, with a third to half of the women reporting moderate-to-severe symptoms. Population surveys suggest that, although prevalence rates vary considerably according to geographical locations, complaints of dysmenorrhea are widespread among diverse populations. Symptoms are frequently associated with time lost from school, work, or other activities. Despite the frequency and severity of dysmenorrhea, most women do not seek medical treatment for this condition.“Dysmenorrhea” is derived from a Greek root word that translates as “difficult menstrual flow.” Dysmenorrhea can be divided into the two broad categories of primary and secondary. Primary dysmenorrhea is defined as a cramping pain in the lower abdomen occurring just before or during menstruation, without pelvic abnormalities. Secondary dysmenorrhea is menstrual pain associated with underlying pelvic pathology such as endometriosis.Primary dysmenorrhea is typically characterized by a menstrual cramp that begins between several hours before and a few hours after onset of menstrual bleeding. Primary dysmenorrhea may be associated with vomiting, fatigue, back pain, headaches, dizziness, and diarrhea. Ninety percent of young women report that the duration of their menstrual cramps is 48 hours or less. Symptoms are relatively repeated from one menstrual period to the next. The pain is characteristically colicky and located in the midline of the lower abdomen. Primary dysmenorrhea arises from the secretion of prostaglandins during the luteal phase and subsequent menstrual flow. Excessive release of prostaglandins increases the amplitude and frequency of uterine contractions and causes vasospasm of the uterine arterioles, resulting in ischaemia and cyclical lower abdominal cramps.In the United States, dysmenorrhea accounts for 600 billion working hours loss and over US$ 2 billion productivity lost every year [1]. In Taiwan, primary dysmenorrhea is the most common reason adolescent girls consult gynecologists.Dysmenorrhea may lead to severe anxiety; thus, if pain during menstruation can be relieved, anxiety levels may also be reduced [2].Many women consider menstrual pain to be inevitable even though the pain is severe and incapacitating. Women suffering from primary dysmenorrhea may not seek medical assistance and frequently do not use available prescription therapies. Anti-inflammatory drugs are generally the first choice of treatment for primary dysmenorrhea. Anti-inflammatory drugs directly inhibit the enzyme of cyclooxygenase (COX-2), indirectly reducing prostaglandin synthesis. However, 20% to 30% of patients with primary dysmenorrhea report that anti-inflammatory drugs are ineffective. In addition, drug therapy provides only temporary relief, and drugs are associated with several gastrointestinal side effects and complications such as anti-inflammatory-induced gastric ulcers or bleeding, and increased load on the kidneys and liver. Thus, an effective alternative therapy without drugs is necessary for the treatment of dysmenorrhea.Research has shown that electromagnetic waves of far-infrared ray (FIR) especially at 4–14μm produce both nonthermal and thermal effects [3–9]. Such effects include an increase in microvascular dilation, higher blood flow volume, and an elevation in regional tissue temperature [3–5]. The consensus view is that these wavelengths promote other intracellular effects at the microscopic level, affecting heat transfer in subcutaneous tissues, and other physiobiological processes [5, 6, 10].Several studies indicated that far-infrared ray irradiation is an effective treatment for chronic pain [10–13]. However, a limited number of studies have used objective parameters to assess the clinical efficacy of FIR, or have attempted to explain its mechanism on a biomolecular basis.This study investigated the therapeutic effect of an FIR-emitting belt (FIRB) on dysmenorrhea by analyzing objective parameters and attempted to explain the possible mechanisms. In this study, participants were assessed during the dysmenorrheal period, and changes were monitored before and after application of the FIRB. Dysmenorrhea was measured quantitatively by thermography, laser Doppler imaging, standard deviation of normal-to-normal RR intervals (SDNN), verbal rating scale (VRS), and numeric rating scale (NRS).


## 2. Materials and Methods

### 2.1. Participants

The clinical trial was approved by an independent ethics committee of the university, with certification by the Institutional Review Board (IRB) approval number HK IRB 98-B-002. We performed this experiment from February 1, 2010 to January 31, 2011.Participants were recruited for the study cohort from campus. Adolescent female students with dysmenorrhea volunteered as candidates and were screened by the doctor. All of the participants were required to complete a pretest questionnaire on their medical history and pain. The questionnaire investigated possible discomfort and other descriptions. The participants were also required to sign a consent form before any measurements were taken or FIRB was applied. The inclusion criteria for all candidates who participated in this study were as follows: older than 18; self-reported dysmenorrhea; no history of major gynecological disease or secondary dysmenorrhea; no pain medication taken in the 24 hours before receiving treatment. Only subjects on the first-to-third days from the onset of menses could be included in this study to treat with the FIRB. The carefully selected sample included forty young women with primary dysmenorrhea.


### 2.2. FIR-Emitting Belt

The FIR spectrum of thecarbon fiber fabric belt (30 cm × 60 cm as shown in Figure1, THERMEDIC, LinkWin Technology Co., Ltd., Taiwan) used in this study was determined by a CI SR5000 spectroradiometer at the Industrial Technology Research Institute, Taiwan. The FIR energy generated from the carbon fiber belt at 50°C is 11.34 mW/cm2 by integrating the intensity of the wavelengths between 4 μm and 16 μm in Figure 2.Figure 1
The photograph of the carbon fiber belt in this study. The belt controller was set to 50°C for 30 minutes.Figure 2
The FIR spectrum of the carbon fiber belt at 50°C. The total intensity of the wavelengths between 4μm and 16 μm is 11.34 mW/cm2.


### 2.3. Measurements

All measurements and procedures in this study were performed in a climate-controlled room at a constant temperature and humidity (23°C and 60% relative humidity). Before assessment, participants were required to lie down in this room to acclimatize to these indoor climatic conditions for 30 minutes [14]. Participants were thermographed for the abdominal region by the Fluke Ti25 (Fluke Corporation, Everett, WA, USA). Their abdominal blood flows were measured by the MoorLDI2-IR laser Doppler imaging (Moor Instruments Ltd., Devon, UK) [15]. Subsequently, they were asked to wear the FIRB on the abdominal region. Then FIRB was warmed to a temperature of 50°C to enhance FIR irradiation for 30 minutes. The second measurements of abdominal temperature and blood flow were performed after the application of FIRB.In addition, ANSWatch wrist monitor (TS-0411, Taiwan Scientific Corp., Taiwan) utilized in studying nervous system regulation [16, 17] was applied to conduct a standard 5-minute heart rate variability (HRV) test with left hand before and after using FIRB  for 30 minutes. The cuff with piezo-electrical sensors obtained blood pressure signals produced by the radial artery, with the aid of an air pouch pressure controlled by an air pump and a release valve. The blood pressure waveforms with peak-to-peak intervals were determined in time domain analysis. The HRV analysis followed closely the 1996 International Standard. HRV is total ANS activity index (ms) that equal to standard deviation of normal-to-normal RR intervals defined in the 1996 international standard [18].


### 2.4. Menstrual Pain Assessment

Before and after the application of FIRB, all the participants were required to complete two pain questionnaires to assess the pain scores associated with their dysmenorrhea. These pain assessments were the five-level verbal rating scale (VRS) and 11-point numeric rating scale (NRS) [19]. The VRS pain scale was classified into grades of none (0), very mild (1), mild (2), moderate (3), severe (4), and very severe (5). The NRS was divided into eleven levels of pain, ranging from no pain (0) to the worst pain (10).


### 2.5. Statistical Analysis

The data differences between before and after treatment were analyzed using Wilcoxon signed-rank test. A value ofP<0.05 was considered statistically significant (*), and P<0.01 was highly significant (**).


## 2.1. Participants

The clinical trial was approved by an independent ethics committee of the university, with certification by the Institutional Review Board (IRB) approval number HK IRB 98-B-002. We performed this experiment from February 1, 2010 to January 31, 2011.Participants were recruited for the study cohort from campus. Adolescent female students with dysmenorrhea volunteered as candidates and were screened by the doctor. All of the participants were required to complete a pretest questionnaire on their medical history and pain. The questionnaire investigated possible discomfort and other descriptions. The participants were also required to sign a consent form before any measurements were taken or FIRB was applied. The inclusion criteria for all candidates who participated in this study were as follows: older than 18; self-reported dysmenorrhea; no history of major gynecological disease or secondary dysmenorrhea; no pain medication taken in the 24 hours before receiving treatment. Only subjects on the first-to-third days from the onset of menses could be included in this study to treat with the FIRB. The carefully selected sample included forty young women with primary dysmenorrhea.


## 2.2. FIR-Emitting Belt

The FIR spectrum of thecarbon fiber fabric belt (30 cm × 60 cm as shown in Figure1, THERMEDIC, LinkWin Technology Co., Ltd., Taiwan) used in this study was determined by a CI SR5000 spectroradiometer at the Industrial Technology Research Institute, Taiwan. The FIR energy generated from the carbon fiber belt at 50°C is 11.34 mW/cm2 by integrating the intensity of the wavelengths between 4 μm and 16 μm in Figure 2.Figure 1
The photograph of the carbon fiber belt in this study. The belt controller was set to 50°C for 30 minutes.Figure 2
The FIR spectrum of the carbon fiber belt at 50°C. The total intensity of the wavelengths between 4μm and 16 μm is 11.34 mW/cm2.


## 2.3. Measurements

All measurements and procedures in this study were performed in a climate-controlled room at a constant temperature and humidity (23°C and 60% relative humidity). Before assessment, participants were required to lie down in this room to acclimatize to these indoor climatic conditions for 30 minutes [14]. Participants were thermographed for the abdominal region by the Fluke Ti25 (Fluke Corporation, Everett, WA, USA). Their abdominal blood flows were measured by the MoorLDI2-IR laser Doppler imaging (Moor Instruments Ltd., Devon, UK) [15]. Subsequently, they were asked to wear the FIRB on the abdominal region. Then FIRB was warmed to a temperature of 50°C to enhance FIR irradiation for 30 minutes. The second measurements of abdominal temperature and blood flow were performed after the application of FIRB.In addition, ANSWatch wrist monitor (TS-0411, Taiwan Scientific Corp., Taiwan) utilized in studying nervous system regulation [16, 17] was applied to conduct a standard 5-minute heart rate variability (HRV) test with left hand before and after using FIRB  for 30 minutes. The cuff with piezo-electrical sensors obtained blood pressure signals produced by the radial artery, with the aid of an air pouch pressure controlled by an air pump and a release valve. The blood pressure waveforms with peak-to-peak intervals were determined in time domain analysis. The HRV analysis followed closely the 1996 International Standard. HRV is total ANS activity index (ms) that equal to standard deviation of normal-to-normal RR intervals defined in the 1996 international standard [18].


## 2.4. Menstrual Pain Assessment

Before and after the application of FIRB, all the participants were required to complete two pain questionnaires to assess the pain scores associated with their dysmenorrhea. These pain assessments were the five-level verbal rating scale (VRS) and 11-point numeric rating scale (NRS) [19]. The VRS pain scale was classified into grades of none (0), very mild (1), mild (2), moderate (3), severe (4), and very severe (5). The NRS was divided into eleven levels of pain, ranging from no pain (0) to the worst pain (10).


## 2.5. Statistical Analysis

The data differences between before and after treatment were analyzed using Wilcoxon signed-rank test. A value ofP<0.05 was considered statistically significant (*), and P<0.01 was highly significant (**).


## 3. Results

### 3.1. Effect of FIRB on Abdominal Temperature

The abdominal temperature was measured by thermography (Fluke Ti25). Results indicated that there was a substantial increase in regional body temperature after participants used FIRB for 30 minutes. It was shown in Figure3. The average abdominal temperatures of before and after FIRB treatment were 34.6 ± 1.2°C and 37.5 ± 1.2°C, respectively. This temperature increase was safe for skin and did not cause any burns in participants. There was no side effect such as menorrhagia reported in the treatment of primary dysmenorrhea with the FIRB.Figure 3
The average abdominal temperatures before and after treatment. Expression values are the mean and standard deviation, and the statistical difference was analyzed by Wilcoxon signed-rank test. Double asterisk mean that this group was highly significantly different from control group (P<0.01).


### 3.2. Effect of FIRB on Blood Flow

The abdominal blood flow was measured by the Moor laser Doppler imaging device (MoorLDI2-IR). A significant increase was found in regional blood perfusion after participants’ use of FIRB for 30 minutes (Figure4). There was a 48.7 ± 49.7% increase in the normalized abdominal blood flow after FIRB treatment.Figure 4
The relative abdominal blood flows before and after treatment. Expression values are the mean and standard deviation, and the difference between groups was tested using Wilcoxon Signed-Rank Test. Double asterisk mean that this group was highly significantly different from control group (P<0.01).


### 3.3. Effect of FIRB on Physiological Signals

No significant differences emerged in the physiological parameters of the blood pressure and respiration between before and after FIRB treatment conditions. However, the standard deviation of normal-to-normal RR intervals in pulse waveforms increased significantly (Figure5). The average SDNN values of before and after FIRB treatment were 69.2 ± 42.2 ms and 97.2 ± 72.8 ms, respectively. This finding may imply that the autonomic nervous system became more active with treatment. It seems possible that FIRB may help relieve pain by regulating the autonomic nervous system.Figure 5
The mean SDNN values before and after treatment. Expression values are the mean and standard deviation, and Wilcoxon Signed-Rank Test was used to test the statistical difference between groups. Asterisk means that this group has statistical difference with control group (P<0.05).


### 3.4. Effect of FIRB on VRS and NRS Scores

The pain assessments by VRS and NRS showed that treatment with FIRB significantly decreased the participants’ subjective ratings of their pain or suffering associated with dysmenorrhea (Figures6 and 7). The average VRS scores before and after FIRB treatment were 1.89 ± 1.02 and 0.76 ± 0.68, respectively. The average NRS scores before and after FIRB treatment were 4.57 ± 1.83 and 1.62 ± 1.62, respectively.Figure 6
The VRS scores before and after treatment. Expression values are the mean and standard deviation, and the statistical difference was detected by Wilcoxon Signed-Rank Test. Asterisk means that this group has statistical difference with control group (P<0.05).Figure 7
The NRS scores before and after treatment. Expression values are the mean and standard deviation, and the difference between groups was analyzed using Wilcoxon Signed-Rank Test. Asterisk means that this group has statistical difference with control group (P<0.05).


## 3.1. Effect of FIRB on Abdominal Temperature

The abdominal temperature was measured by thermography (Fluke Ti25). Results indicated that there was a substantial increase in regional body temperature after participants used FIRB for 30 minutes. It was shown in Figure3. The average abdominal temperatures of before and after FIRB treatment were 34.6 ± 1.2°C and 37.5 ± 1.2°C, respectively. This temperature increase was safe for skin and did not cause any burns in participants. There was no side effect such as menorrhagia reported in the treatment of primary dysmenorrhea with the FIRB.Figure 3
The average abdominal temperatures before and after treatment. Expression values are the mean and standard deviation, and the statistical difference was analyzed by Wilcoxon signed-rank test. Double asterisk mean that this group was highly significantly different from control group (P<0.01).


## 3.2. Effect of FIRB on Blood Flow

The abdominal blood flow was measured by the Moor laser Doppler imaging device (MoorLDI2-IR). A significant increase was found in regional blood perfusion after participants’ use of FIRB for 30 minutes (Figure4). There was a 48.7 ± 49.7% increase in the normalized abdominal blood flow after FIRB treatment.Figure 4
The relative abdominal blood flows before and after treatment. Expression values are the mean and standard deviation, and the difference between groups was tested using Wilcoxon Signed-Rank Test. Double asterisk mean that this group was highly significantly different from control group (P<0.01).


## 3.3. Effect of FIRB on Physiological Signals

No significant differences emerged in the physiological parameters of the blood pressure and respiration between before and after FIRB treatment conditions. However, the standard deviation of normal-to-normal RR intervals in pulse waveforms increased significantly (Figure5). The average SDNN values of before and after FIRB treatment were 69.2 ± 42.2 ms and 97.2 ± 72.8 ms, respectively. This finding may imply that the autonomic nervous system became more active with treatment. It seems possible that FIRB may help relieve pain by regulating the autonomic nervous system.Figure 5
The mean SDNN values before and after treatment. Expression values are the mean and standard deviation, and Wilcoxon Signed-Rank Test was used to test the statistical difference between groups. Asterisk means that this group has statistical difference with control group (P<0.05).


## 3.4. Effect of FIRB on VRS and NRS Scores

The pain assessments by VRS and NRS showed that treatment with FIRB significantly decreased the participants’ subjective ratings of their pain or suffering associated with dysmenorrhea (Figures6 and 7). The average VRS scores before and after FIRB treatment were 1.89 ± 1.02 and 0.76 ± 0.68, respectively. The average NRS scores before and after FIRB treatment were 4.57 ± 1.83 and 1.62 ± 1.62, respectively.Figure 6
The VRS scores before and after treatment. Expression values are the mean and standard deviation, and the statistical difference was detected by Wilcoxon Signed-Rank Test. Asterisk means that this group has statistical difference with control group (P<0.05).Figure 7
The NRS scores before and after treatment. Expression values are the mean and standard deviation, and the difference between groups was analyzed using Wilcoxon Signed-Rank Test. Asterisk means that this group has statistical difference with control group (P<0.05).


## 4. Discussion

The etiology of primary dysmenorrhea is bounded in a multiplicity of pathological, mechanical, and psychoneurotic disorders. One disorder that has been found to correlate with primary dysmenorrhea is blood flow deprivation with organic and lower abdominal ischemia. The sensation of pain and related biomolecule induction of COX-2 and prostaglandin are strongly related to the severity of primary dysmenorrhea. Previous studies have identified the overproduction of uterine prostaglandins as a contributing factor to primary dysmenorrhea. The most widely used anti-inflammatory drugs for primary dysmenorrhea directly inhibit the cyclooxygenase (COX) enzymes, thereby inhibiting the production of prostaglandins. Prostaglandin synthesis is mediated primarily by two distinct isoforms of cyclooxygenase (COX-1 and COX-2), which catalyze the metabolism of arachidonate to prostaglandin H2. Conventional anti-inflammatory drugs act as nonselective inhibitors of both isoforms of COX. It has been proposed that the therapeutic efficacy of anti-inflammatory drugs is primarily the result of COX-2 inhibition. Cyclooxygenase (including COX-2) inhibitors have been developed clinically as a treatment for dysmenorrhea.Far-infrared radiation offers a nondrug alternative therapy to relieve inflammation by targeting prostaglandin and COX-2. Our earlier study had investigated a FIR-emitting ceramic material with a focus on basic medical science of cells and animal models. We found that the FIR-emitting ceramic material promoted microcirculation and induced other effects by upregulating calcium-dependent nitric oxide (NO) and calmodulin in different cell lines [5, 6]. We manifested that the FIR ceramic material exerted an antioxidant effect by increasing the hydrogen peroxide-scavenging ability in different cells lines [7, 8]. We also illustrated that FIR induced anti-inflammatory effects by inhibiting prostaglandin (PGE-2) in SW1353 human chondrosarcoma cell line [20]. In addition, our unpublished data show that FIR irradiation had significant inhibition of COX-2 elevation during lipopolysaccharide-induced inflammation in both murine macrophages and human chondrosarcoma cell line.Ischemia is mainly a consequence of decreased microcirculation or a reduction in local muscle blood flow and perfusion. This scenario has important consequences for cellular metabolic status, with a significantly worsened metabolic and acid-base status while acidosis is accumulated. During dysmenorrhea, the corresponding regional organic ischemia is associated with increased oxidative stress due to increased levels of reactive oxygen species (ROS), such as superoxide and hydrogen peroxide (H2O2), which are responsible of destructive processes in organic tissues [7, 8]. Our previously published data indicated that FIR-irradiating ceramic material produced calcium-dependent NO [5, 6]. It is a medical fact that NO is essential to female-related cells such as uterine and placental cells. During menstruation and pregnancy, women need to produce more NO in the related cells. Recent medical research has indicated that diminished levels of NO induce myometrial contractions, while NO can cause uterine relaxation. By using oral glyceryl trinitrate as a source of NO can relax the exaggerated myometrial contractions in primary dysmenorrhea. A recent review concluded that nitroglycerin significantly reduces the pain in primary dysmenorrheal [21].Several important merits of NO and the NO-related biomolecules suggest the mechanisms by which dysmenorrhea is alleviated. First, NO inhibits platelet aggregation, reducing inflammation and providing pain relief. Second, adequate NO activity can improve microcirculation, which is a protective factor in maintaining the smooth muscle dilation of blood vessels. Because NO increases blood flow, microcirculation in the endometrial tissue is enhanced, thus relieving inflammation and dysmenorrhea. Third, dysmenorrhea is due to rapid and strong uterine contractions. NO helps coordinate and relieve smooth muscle contraction and relaxation [22]. Fourth, NO is involved in the endocrine mechanism by which menstruation is initiated. Finally, an exogenous NO donor, glyceryl trinitrate, is already in use as medication to relieve dysmenorrhea by local application. Glyceryl trinitrate has a relaxing effect on the myometrium and has been shown to have a beneficial effect on primary dysmenorrheal [23, 24].Primary dysmenorrhea as a psychoneurotic disorder is the most common reason for adolescent girls to consult a gynecologist in Taiwan. Primary dysmenorrhea may lead to severe anxiety. If the dysmenorrheal pain can be relieved, anxiety may also be reduced [2]. Some researchers have suggested using cardiac vagal tone as a novel index of stress and stress-induced pain. The role of the parasympathetic nervous system and particularly the vagus nerve in defining stress has been demonstrated [25]. This study finds that the prolonging of the standard deviation of normal-to-normal RR intervals by FIRB has an effect of relaxation. The relaxation response is controlled by the parasympathetic nervous system and particularly the vagus nerve. This relaxation response is a palliative treatment for pain, and the enhancement of parasympathetic tone is important to apply on different chronic pain control. Automatic nervous system pain regulation by parasympathetic activation via the vagal pathways has been shown to exert a beneficial effect on pain and to produce a relaxation response, included in the treatment of dysmenorrhea [25–28].The thermal effect of the FIRB is also involved in the treatment of primary dysmenorrhea. Thermal effect individually exhibits some degree of relieving symptoms of dysmenorrhea. One of the mechanisms is warm temperature inhibiting sympathetic nerve activities that are responsible of the pain sensation. Besides, the inhibition of sympathetic nerve activity by warm temperature application on lower abdominal or lumbar region might increase uterine blood flow and remove pain-producing substances [29, 30]. In addition, heat can treat dysmenorrhea through a form of gate control or by altering pain thresholds centrally or through an altered sense of well-being [31].Although the therapeutic efficacy of the FIRB had been found in this study, there are some limitations in the interpretation of our findings. This is a self-controlled before-and-after experimental study. In spite of the valid physical evidence without a control group, psychological effects may exist in self-report assessments and affect the pain scores. Future studies are suggested to be designed with a larger sample-sized, randomized, and controlled group to further illustrate the psychoneurotic factors.


## 5. Conclusions

This study demonstrated that FIRB is an effective and safe form of therapy for primary dysmenorrhea. Treatment by FIRB resulted in a significant elevation of temperature and abdominal blood flow as well as effective pain relief assayed by the VRS and NRS. Based on these findings and previous literatures, we speculated that the possible effect of FIR on dysmenorrhea may include NO induction, scavenging oxidative stress, and suppression of COX-2 and PGE2 production. FIRB significantly increased the average SDNN value, reflecting that autonomic tone was modulated for relaxation during menstrual pain. This increase in heart rate variability may explain the effect of FIRB on the relationship between pain, anxiety, and activation of the autonomic nervous system. Therefore, it indicates that FIRB may help relieve dysmenorrhea by regulating the autonomic nervous system.



---

*Source: 238468-2012-07-05.xml*